Heart sounds

Proven auscultation leader 3M Littmann Stethoscopes are now available with an innovative Satin Finish tubing

Retrieved on: 
Tuesday, January 16, 2024
Midnight, Cardiology, Stethoscope, Leptotes marina, Korotkov, Clothing, S3, Mitral stenosis, Heart sounds, Life

Studies have shown that 3M™ Littmann® Stethoscopes' Cardiology IV™ and Classic III™ Stethoscopes are more than twice as loud as the next leading competitor.

Key Points: 
  • Studies have shown that 3M™ Littmann® Stethoscopes' Cardiology IV™ and Classic III™ Stethoscopes are more than twice as loud as the next leading competitor.
  • Select models of these outstanding stethoscopes are now available with a specially-formulated tubing for a softer, silkier more flexible feel for easier folding and stowing*.
  • "For health care professionals, the 3M Littmann brand is globally-recognized for quality, reliability and innovation, but also style," said Craig Conti, global portfolio leader, Littmann Stethoscope, 3M Health Care Business Group.
  • Littmann stethoscopes Satin Finish tubing is available in the United States now at Authorized Littmann Dealers and will roll out globally throughout 2024.

dBio Unveils Cutting-Edge AIoT Health Innovations at Medica 2023

Retrieved on: 
Tuesday, November 14, 2023
Cloud, Research, Exercise, Stethoscope, GAIT, Artificial intelligence, Heart sounds, Health, Medica, Gait analysis, Software, Artificial intelligence of things, Medical device

TAIPEI, Nov. 14, 2023 /PRNewswire/ -- Get ready for an extraordinary health adventure with dBio at Medica 2023!

Key Points: 
  • TAIPEI, Nov. 14, 2023 /PRNewswire/ -- Get ready for an extraordinary health adventure with dBio at Medica 2023!
  • Decentralized Biotechnology Intelligence Co., Ltd (dBio) was awarded the 20th National Innovation Award for their latest solutions, the AIoT Wearable Stethoscope (StethoCloud) and AIoT Smart Insole Sensor (gMOT Cloud) .
  • These innovations promise to provide the most convenient and user-oriented way to monitor and manage our health, all in ultra-slim, user-friendly AIoT solutions.
  • dBio invites you to experience the future of health and exercise innovation at Medica 2023, from November 13 to November 16 in Düsseldorf.

TytoCare Receives FDA Clearance for its AI-Powered Tyto Insights™ for Wheeze Detection to Ensure Diagnostic Accuracy from Home

Retrieved on: 
Wednesday, March 15, 2023
Wheeze, Heart sounds, CE marking, Long-term care, Auscultation, Vital signs, Database, Patient, Algorithm, Nature, Tyto, ViVe, FDA, Asthma, Ageing, AI, ROI, Entrepreneurship, Lung, Nursing, Medical device

NEW YORK, March 15, 2023 /PRNewswire/ -- TytoCare, a virtual care company enabling accessible, high-quality primary care from home, today announced that it received FDA clearance for its Tyto Insights™ for Wheeze Detection, paving the way for its rollout in the US. The wheeze detection algorithm expands the company's existing AI-powered Tyto Insights™ smart diagnostic capabilities, filling the quality gaps currently experienced with traditional telehealth and alleviating challenges imposed by the ongoing shortage of healthcare professionals.

Key Points: 
  • The wheeze detection algorithm expands the company's existing AI-powered Tyto Insights™ smart diagnostic capabilities, filling the quality gaps currently experienced with traditional telehealth and alleviating challenges imposed by the ongoing shortage of healthcare professionals.
  • Whenever a remote lung exam is carried out with TytoCare, Tyto Insights for Wheeze Detection prompts a clinician if a specific abnormal lung sound suggestive of wheezing is suspected.
  • The FDA clearance comes as TytoCare is continually strengthening its offerings to provide the best possible virtual primary care from home with its Home Smart Clinic.
  • The Tyto Insights for Wheeze Detection already bears the CE Mark for usage by clinicians in Europe.

Eko Launches SENSORA™ Cardiac Disease Detection Platform

Retrieved on: 
Thursday, February 23, 2023
ECG, Death, VHD, Cardiovascular disease, University of California, San Francisco, Arrhythmia, ACC, Learning, University, Artificial intelligence, Heart, Heart sounds, Assistant, Algorithm, FDA, Valvular heart disease, Department of Medicine – University of Pamplona, Patient, San Francisco, Heart failure, Economics, Pulmonary hypertension, Division, San Francisco General Hospital, Machine learning, Thrombus, Stethoscope, Length of stay, Stroke, Hospital, Medical device, Nursing, Medical imaging, Cardiology

OAKLAND, Calif., Feb. 23, 2023 /PRNewswire/ -- Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA™ Cardiac Disease Detection Platform. SENSORA™ currently features AI that objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.

Key Points: 
  • OAKLAND, Calif., Feb. 23, 2023 /PRNewswire/ -- Eko , a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA™ Cardiac Disease Detection Platform.
  • SENSORA™ is a cardiovascular disease detection platform that combines the latest advancements in applied machine learning with one of the most ubiquitous medical devices in the world: the stethoscope.
  • By capturing and analyzing heart sounds and electrical signals with its digital stethoscopes, Eko has pioneered a detection platform designed to expand as the company develops applications for additional cardiac conditions.
  • "Our vision for SENSORA™ is to make cardiovascular disease detection simple and accurate in frontline care settings like primary care and urgent care," said Connor Landgraf, Co-founder & CEO of Eko.

Eko Named to 2022 CB Insights Digital Health 150

Retrieved on: 
Thursday, December 8, 2022
CB Insights, Heart, Digital technology, R, AR, Economist Intelligence Unit, Health, Patient, Heart sounds, Research, Digital, Rest, FDA, SVP, Artificial intelligence, Stethoscope, Digital health, Degenerative disease, Machine learning, Medical device, Diagnosis, Mosaic

OAKLAND, Calif., Dec. 8, 2022 /PRNewswire/ -- Eko, a digital health company applying machine learning in the fight against heart and lung disease, today announced that it was named to the 2022 CB Insights Digital Health 150 list. This is the third consecutive year that Eko has been included in the list of 150 of the most promising, private digital healthcare companies in the world.

Key Points: 
  • OAKLAND, Calif., Dec. 8, 2022 /PRNewswire/ -- Eko , a digital health company applying machine learning in the fight against heart and lung disease, today announced that it was named to the 2022 CB Insights Digital Health 150 list .
  • This is the third consecutive year that Eko has been included in the list of 150 of the most promising, private digital healthcare companies in the world.
  • "From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year's Digital Health 150 winners are transforming the future of healthcare with digital technology," said Brian Lee, SVP of CB Insights' Intelligence Unit.
  • Eko is committed to impacting patient care in a meaningful way by providing digital tools that solve important clinical problems."

FDA Clears Eko's Heart Disease Detection AI for Adults and Pediatrics

Retrieved on: 
Tuesday, July 12, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Method, Valvular heart disease, Cardiovascular disease, Character, Phonocardiogram, GP, Health, Practitioner, Highland Capital Partners, Stethoscope, Centers for Disease Control and Prevention, European Heart Journal, ECG, Patient, CEO, EMAS, Adult, Center, Heart, Food, Algorithm, Database, Degenerative disease, Heart sounds, Northwestern Medicine, Diagnosis, FDA, Heart murmur, Sutter Health, Software, Medicine, Mayo Clinic, Medical imaging, Medical device, Pharmaceutical industry, S1

OAKLAND, Calif., July 12, 2022 /PRNewswire/ -- Eko, a digital health company advancing heart and lung disease detection, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Eko Murmur Analysis Software (EMAS) for detecting and characterizing murmurs found in adults and pediatric patients. The next generation of Eko's murmur detection capabilities grants Eko the first and only smart stethoscope on the market that can identify and differentiate, between innocent and structural, heart murmurs indicative of valvular heart disease.

Key Points: 
  • The next generation of Eko's murmur detection capabilities grants Eko the first and only smart stethoscope on the market that can identify and differentiate, between innocent and structural, heart murmurs indicative of valvular heart disease.
  • Valvular heart disease is a life-threatening condition diagnosed in more than 8 million Americans1and is often first identified with a stethoscope.
  • "By making heart disease screening algorithms and digital stethoscopes accessible in exam rooms around the country, we are moving towards a future in which more objective and consistent valvular heart disease screening can become the standard of care."
  • Cardiac auscultation poorly predicts the presence of valvular heart disease in asymptomatic primary care patients, Heart 2018;104:18321835. doi:10.1136/heartjnl-2018-313082

Eko Recognized with Second Consecutive MedTech Breakthrough Award for AI Innovation in Healthcare

Retrieved on: 
Thursday, May 5, 2022
Patient engagement in Canada, Atrial fibrillation, Ventricular fibrillation, Journal of the American Heart Association, Global health, Fitness, GLOBE, Â, Algorithm, Neck, Degenerative disease, Heart failure, Highland Capital Partners, Cardiovascular disease, Mayo Clinic, Heart, Patient, Exercise, Heart sounds, Valvular heart disease, Program, FDA, Diagnosis, Incidence, Hospital, Sutter Health, Journal, Artificial intelligence, Workflow, Leadership, MHealth, Health, Medtech, Stethoscope, ECG, American Heart Association, CEO, Technology, Genomic and Medical Data, Intelligence, Pharmaceutical industry, Medical device, Health care

MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market.

Key Points: 
  • MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market.
  • This technology provides frontline healthcare professionals with a reliable, affordable, and scalable solution to screen for cardiovascular disease.
  • The result is improved diagnosis and this technology from Eko is a true breakthrough in every sense of the word.
  • The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more.

3M Littmann CORE Digital Stethoscope Honored in Fast Company's 2022 World Changing Ideas Awards

Retrieved on: 
Tuesday, May 3, 2022
Social justice, Fast Company, Littmann, Health, Degenerative disease, NYSE, Highland Capital Partners, Auscultation, Mayo Clinic, Heart, Patient, Stethoscope, Heart sounds, Creativity, FDA, Climate change, Food, Sutter Health, Adult, Social inequality, Disease, Science, Education, View, Climate, Life, Goal, CEO, Technology, Politics, Transport, AI, Pathology, Multimedia, Medical device, Cassette tape

ST. PAUL, Minn., May 3, 2022 /PRNewswire/ -- 3M Littmann today announced its 3M Littmann CORE Digital Stethoscope received honorable mention accolades in the health category of the 2022 Fast Company World Changing Ideas global awards program recognizing companies, products and initiatives that support innovation for the public good and tackle social inequality, climate change and public health crises.

Key Points: 
  • ST. PAUL, Minn., May 3, 2022 /PRNewswire/ -- 3M Littmann today announced its 3M Littmann CORE Digital Stethoscope received honorable mention accolades in the health category of the 2022 Fast Company World Changing Ideas global awards program recognizing companies, products and initiatives that support innovation for the public good and tackle social inequality, climate change and public health crises.
  • Currently available in 21 countries, the 3M Littmann CORE Digital Stethoscope is a first-of-its-kind smart stethoscope.
  • Released in October 2020, it marries best-in-class 3M Littmann technology with advanced digital innovations from Eko, a digital health company advancing heart and lung disease detection.
  • The 3M Littmann CORE Digital Stethoscope is our most advanced stethoscope yet andwe believe it will help the world tackle heart disease, one preventative screening at a time," said Kristi Barnett, 3M medical devices senior director.

3M Littmann CORE Digital Stethoscope Honored in Fast Company's 2022 World Changing Ideas Awards

Retrieved on: 
Tuesday, May 3, 2022
Social justice, Fast Company, Littmann, Health, Degenerative disease, NYSE, Highland Capital Partners, Auscultation, Mayo Clinic, Heart, Patient, Stethoscope, Heart sounds, Creativity, FDA, Climate change, Food, Sutter Health, Adult, Social inequality, Disease, Science, Education, Climate, Life, Goal, CEO, Technology, Politics, Transport, AI, Pathology, Medical device, Cassette tape

ST. PAUL, Minn., May 3, 2022 /PRNewswire/ -- 3M Littmann today announced its 3M Littmann CORE Digital Stethoscope received honorable mention accolades in the health category of the 2022 Fast Company World Changing Ideas global awards program recognizing companies, products and initiatives that support innovation for the public good and tackle social inequality, climate change and public health crises.

Key Points: 
  • ST. PAUL, Minn., May 3, 2022 /PRNewswire/ -- 3M Littmann today announced its 3M Littmann CORE Digital Stethoscope received honorable mention accolades in the health category of the 2022 Fast Company World Changing Ideas global awards program recognizing companies, products and initiatives that support innovation for the public good and tackle social inequality, climate change and public health crises.
  • Currently available in 21 countries, the 3M Littmann CORE Digital Stethoscope is a first-of-its-kind smart stethoscope.
  • The 3M Littmann CORE Digital Stethoscope is our most advanced stethoscope yet andwe believe it will help the world tackle heart disease, one preventative screening at a time," said Kristi Barnett, 3M medical devices senior director.
  • World Changing Ideas is one of Fast Company's major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better.

Training Manikins Market Forecast Report 2021-2028 - Opportunities in the Application of Robotics, Artificial Intelligence, Augmented Reality, and 3D Printing - ResearchAndMarkets.com

Retrieved on: 
Friday, April 22, 2022
Technology, Medical Devices, Infectious Diseases, Engineering, Other Technology, Manufacturing, Practice Management, Electronic Design Automation, General Health, Health, Neonatal Resuscitation Program, Awareness, BP, Heart sounds, Obstetrics, Mannequin, Intubation, COVID-19, Pediatrics, Resuscitation, Hospital, CAGR, Enema, Death, EKG, Pediatrics (journal), Growth, CPR, OHCA, Application, Technology, Maintenance, Infant, American Academy, Prevalence, Health, NRP, Medicine

The "Training Manikins Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Training Manikins Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, and Application" report has been added to ResearchAndMarkets.com's offering.
  • The Training Manikins market is projected to reach US$ 1,235.61 million by 2028 from US$ 2,603.89 million in 2021.
  • The growth of the training manikins market is attributed to technological advancements and the increasing prevalence of out-of-hospital cardiac arrests and cardiopulmonary resuscitation training and awareness programs.
  • Based on type, the global training manikins market is segmented into CPR training manikins, infant manikins, and others.